ישראל - עברית - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - אבקה להמסה להזרקה\אינפוזיה - c - 1 esterase inhibitor human 500 iu/vial - c1- inhibitor,plasma derived - c1- inhibitor,plasma derived - hereditary angioedema type i and ii (hea) , treatment of acute episodes.

ישראל - עברית - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - אבקה וממס להכנת תמיסה להזרקה - c - 1 esterase inhibitor human 2000 iu/vial - c1- inhibitor,plasma derived

ישראל - עברית - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - אבקה וממס להכנת תמיסה להזרקה - c - 1 esterase inhibitor human 3000 iu/vial - c1- inhibitor,plasma derived

ישראל - עברית - Ministry of Health

neopharm cure (2005) ltd - c - 1 esterase inhibitor human 500 units - lyophilized powder for solution for injection - c1-inhibitor - treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (hae). routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (hae), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

ישראל - עברית - Ministry of Health

csl behring ltd., israel - human fibrinogen - אבקה להמסה להזרקה\אינפוזיה - human fibrinogen 900 - 1300 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

ישראל - עברית - Ministry of Health

csl behring ltd., israel - human fibrinogen - אבקה להמסה להזרקה\אינפוזיה - human fibrinogen 1800 - 2600 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

ישראל - עברית - Ministry of Health

cts ltd - human fibrinogen; thrombin - sponge - thrombin 2 iu/cm2; human fibrinogen 5.5 mg/cm2 - human fibrinogen - human fibrinogen - tachosil is indicated for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for sutute support in vascular surgery where standard techniques are insufficient.

ישראל - עברית - Ministry of Health

takeda israel ltd - factor viii inhibitor bypassing fraction - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii inhibitor bypassing fraction 500 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - for the control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors.

ישראל - עברית - Ministry of Health

takeda israel ltd - factor viii inhibitor bypassing fraction - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii inhibitor bypassing fraction 1000 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - for the control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors .

ישראל - עברית - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - תמיסה לאינפוזיה - human hepatitis b immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - prophylaxis against hepatitis b in adults and children over 2 years of age who have not been vaccinated against hepatitis b (including persons whose vaccination is incomplete or missing) who are at risk of infection with hepatitis b by accidental contact with hepatitis b virus containing material following: - percutaneous exposure (e.g. accidental needle stick). - direct mucous membrane contact. when the administration of an intramuscular hepatitis b immunoglobulin is not possible. the immunoglobulin should be administered in association with hepatitis b vaccine. prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of the hepatitis b virus. immunoprophylaxis of hepatitis b in the newborn of a hepatitis b virus carrier mother.